AOP Orphan is a European pioneer in the development, production and marketing of treatments for people with rare diseases also known as orphan diseases.
“AOP Orphan focuses on supporting the needs of the most vulnerable, often forgotten groups of patients - those with rare diseases. At AOP Orphan, we not only enable access to rare disease therapies, but also provide our competencies to support the entire treatment process.”
“It is our privilege to cooperate with outstanding specialists and to support them to the best of our abilities in order to help patients with rare disorders.”
AOP Orphan is fully dedicated to pharmaceutical and clinical development as well as commercialization of drugs for more than 20 years already.
Our motivation at AOP Orphan is to help patients who suffer from rare diseases. We achieve this cooperating with stakeholders of the Polish health care system. Partnerships within pharmaceutical and health care industry are crucial for finding and providing solutions for patients, especially in the treatment of orphan diseases.
Poland occupies a special position among many countries where AOP Orphan is represented. In this market, the company began its development in 2002 and this is where AOP Orphan also has one of its biggest local teams of around fifteen employees in the Marketing & Sales, and Medical for all three therapeutic divisions.